Open Access

ARTICLE

H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus

by YI-NONG CHEN^1,#, YING-LIN CHEN^1,#, WAN-MING CHEN^2,3, MINGCHIH CHEN^2,3, BEN-CHANG SHIA^2,3, JENQ-YUH KO^1,4, SZU-YUAN WU^{2,3,5,6,7,8,9,10,11,*}

1 Department of Otorhinolaryngology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan
2 Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan
3 Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, Taiwan
4 Department of Otolaryngology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
5 Department of Food Nutrition and Health Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan
6 Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan
7 Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan
8 Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan
9 Cancer Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan
10 Centers for Regional Anesthesia and Pain Medicine, Taipei Municipal Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
11 Department of Management, College of Management, Fo Guang University, Yilan, Taiwan

* Corresponding Author: Szu-Yuan Wu,
# These authors have contributed equally to this study (joint primary authors)

Oncology Research 2023, 31(1), 23-34. https://doi.org/10.32604/or.2022.028449

Received 18 December 2022; Accepted 02 February 2023; Issue published 01 March 2023

Abstract

This study aimed to examine the association between the use of H1-antihistamines (AHs) and head and neck cancer (HNC) risk in patients with type 2 diabetes mellitus (T2DM). Data from the National Health Insurance Research Database of Taiwan were analyzed for the period from 2008 to 2018. A propensity-score-matched cohort of 54,384 patients each in the AH user and nonuser groups was created and analyzed using Kaplan-Meier method and Cox proportional hazards regression. The results showed that the risk of HNC was significantly lower in AH users (adjusted hazard ratio: 0.55, 95% CI: 0.48 to 0.64) and the incidence rate was also lower (5.16 vs. 8.10 per 100,000 person-years). The lower HNC incidence rate in AH users (95% CI: 0.63; 0.55 to 0.73) suggests that AH use may reduce the risk of HNC in T2DM patients.

---

Keywords

---